Products - Colorectal cancer | Topic | NICE

Showing 9 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [TSID12305]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Artificial intelligence software to help detect and characterise colorectal polyps
Status:
In development
Programme:
Diagnostics guidance
Expected publication date:
TBC
Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
25 February 2026
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 September 2026
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) (TA1118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 January 2026
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
21 May 2026
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026